Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Endologix Inc /de/ (ELGX) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Endologix Inc /de/. Table 2 shows the detailed insider transactions. This company's CIK number is 1013606.
Total stock buying since 2014: $1,926,254.
Total stock sales since 2014: $2,297,914.
Total stock option exercises since 2014: $1,372,074.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2020 | 0 | $0 | 235,201 | $41,967 | 0 | $0 |
| 2019 | 71,102 | $469,983 | 4,121 | $24,744 | 0 | $0 |
| 2018 | 30,000 | $72,900 | 16 | $90 | 427,065 | $1,140,263 |
| 2017 | 74,722 | $329,126 | 0 | $0 | 0 | $0 |
| 2016 | 49,000 | $334,870 | 44,541 | $485,700 | 4,710 | $35,466 |
| 2015 | 33,500 | $302,645 | 84,688 | $1,177,060 | 30,853 | $196,345 |
| 2014 | 37,000 | $416,730 | 40,287 | $568,353 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2020-09 | 0 | $0 | 51,844 | $2,644 | 0 | $0 |
| 2020-08 | 0 | $0 | 183,357 | $39,323 | 0 | $0 |
| 2019-11 | 0 | $0 | 582 | $1,746 | 0 | $0 |
| 2019-08 | 0 | $0 | 2,084 | $13,775 | 0 | $0 |
| 2019-05 | 0 | $0 | 1,455 | $9,223 | 0 | $0 |
| 2019-04 | 71,102 | $469,983 | 0 | $0 | 0 | $0 |
| 2018-08 | 30,000 | $72,900 | 0 | $0 | 0 | $0 |
| 2018-05 | 0 | $0 | 16 | $90 | 177,065 | $472,763 |
| 2018-03 | 0 | $0 | 0 | $0 | 250,000 | $667,500 |
| 2017-05 | 74,722 | $329,126 | 0 | $0 | 0 | $0 |
| 2016-12 | 33,000 | $211,230 | 0 | $0 | 0 | $0 |
| 2016-11 | 16,000 | $123,640 | 0 | $0 | 0 | $0 |
| 2016-08 | 0 | $0 | 18,710 | $228,612 | 4,710 | $35,466 |
| 2016-06 | 0 | $0 | 11,051 | $141,107 | 0 | $0 |
| 2016-05 | 0 | $0 | 6,500 | $82,940 | 0 | $0 |
| 2016-02 | 0 | $0 | 4,000 | $0 | 0 | $0 |
| 2016-01 | 0 | $0 | 4,280 | $33,041 | 0 | $0 |
| 2015-11 | 33,500 | $302,645 | 0 | $0 | 0 | $0 |
| 2015-09 | 0 | $0 | 1,923 | $24,229 | 0 | $0 |
| 2015-08 | 0 | $0 | 1,250 | $15,787 | 0 | $0 |
| 2015-05 | 0 | $0 | 21,515 | $357,044 | 15,853 | $130,945 |
| 2015-04 | 0 | $0 | 45,000 | $780,000 | 0 | $0 |
| 2015-03 | 0 | $0 | 15,000 | $0 | 15,000 | $65,400 |
| 2014-12 | 0 | $0 | 10,000 | $139,550 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-09-04 | Lemaitre Dan | Sale | 51,844 | .05 | 2,644 |
| 2020-08-14 | Lemaitre Dan | Sale | 1,127 | .08 | 92 |
| 2020-08-13 | Lemaitre Dan | Sale | 1,126 | .09 | 97 |
| 2020-08-12 | Pinto Cynthia Buch (Interim CFO) | Sale | 12,003 | .09 | 1,056 |
| 2020-08-12 | Brady Timothy Nicholas (Controller and Corp Secretary) | Sale | 1,741 | .08 | 144 |
| 2020-08-12 | Thompson Matthew (Chief Medical Officer) | Sale | 21,888 | .09 | 1,926 |
| 2020-08-12 | Wilder Thomas | Sale | 27,864 | .08 | 2,284 |
| 2020-08-12 | Onopchenko John (CEO and Director) | Sale | 88,978 | .35 | 31,320 |
| 2020-08-12 | Waller Gregory D | Sale | 28,630 | .08 | 2,404 |
| 2019-11-11 | Waller Gregory D | Sale | 582 | 3.00 | 1,746 |
| 2019-08-14 | Wilder Thomas | Sale | 1,369 | 6.61 | 9,049 |
| 2019-08-14 | Waller Gregory D | Sale | 715 | 6.61 | 4,726 |
| 2019-05-07 | Wilder Thomas | Sale | 1,455 | 6.34 | 9,223 |
| 2019-04-03 | Mahboob Vaseem (Chief Financial Officer) | Buy | 15,128 | 6.61 | 99,996 |
| 2019-04-03 | Zenty Iii Thomas F | Buy | 3,025 | 6.61 | 19,995 |
| 2019-04-03 | Onopchenko John (CEO and Director) | Buy | 30,257 | 6.61 | 199,998 |
| 2019-04-03 | Neels Guido J | Buy | 22,692 | 6.61 | 149,994 |
| 2018-08-16 | Mahboob Vaseem (Chief Financial Officer) | Buy | 30,000 | 2.43 | 72,900 |
| 2018-05-29 | Chavez Christopher G. | Sale | 16 | 5.67 | 90 |
| 2018-05-10 | Mcdermott John D | Option Ex | 177,065 | 2.67 | 472,763 |
| 2018-03-27 | Mcdermott John D (Chief Executive Officer) | Option Ex | 250,000 | 2.67 | 667,500 |
| 2017-05-22 | Lemaitre Dan | Buy | 22,522 | 4.43 | 99,772 |
| 2017-05-22 | Zenty Iii Thomas F | Buy | 5,000 | 4.44 | 22,200 |
| 2017-05-19 | Mcdermott John D (Chief Executive Officer) | Buy | 25,000 | 4.45 | 111,250 |
| 2017-05-19 | Mitchell Robert D (President) | Buy | 2,200 | 4.32 | 9,504 |
| 2017-05-19 | Neels Guido J | Buy | 20,000 | 4.32 | 86,400 |
| 2016-12-14 | Mcdermott John D (Chief Executive Officer) | Buy | 10,000 | 6.67 | 66,700 |
| 2016-12-14 | Zenty Iii Thomas F | Buy | 3,000 | 6.51 | 19,530 |
| 2016-12-13 | Mahboob Vaseem (Chief Financial Officer) | Buy | 20,000 | 6.25 | 125,000 |
| 2016-11-18 | Zenty Iii Thomas F | Buy | 3,000 | 7.89 | 23,670 |
| 2016-11-18 | Neels Guido J | Buy | 13,000 | 7.69 | 99,970 |
| 2016-08-19 | Lima Jose A. (VP-Quality) | Sale | 4,710 | 11.68 | 55,012 |
| 2016-08-19 | Lima Jose A. (VP-Quality) | Option Ex | 4,710 | 7.53 | 35,466 |
| 2016-08-05 | Chobotov Michael V. (Chief Technology Officer) | Sale | 14,000 | 12.40 | 173,600 |
| 2016-06-03 | Waller Gregory D | Sale | 7,800 | 12.86 | 100,308 |
| 2016-06-01 | Machek James Edward (VP-Research & Development) | Sale | 957 | 12.55 | 12,010 |
| 2016-06-01 | Mitchell Robert D (President) | Sale | 2,294 | 12.55 | 28,789 |
| 2016-05-26 | Machek James Edward (VP-Research & Development) | Sale | 6,500 | 12.76 | 82,940 |
| 2016-02-29 | O'quinn Shari L (VP, Clinical & Regulatory) | Sale | 4,000 | .00 | 0 |
| 2016-01-26 | Love Charles Steele (VP-Clinical Affairs) | Sale | 4,280 | 7.72 | 33,041 |
| 2015-11-03 | Abraham Todd (VP of Operations) | Buy | 2,500 | 8.85 | 22,125 |
| 2015-11-03 | Neels Guido J | Buy | 11,000 | 9.32 | 102,520 |
| 2015-11-02 | Mcdermott John D (Chief Executive Officer) | Buy | 20,000 | 8.90 | 178,000 |
| 2015-09-03 | Lima Jose A. (VP-Quality) | Sale | 1,923 | 12.60 | 24,229 |
| 2015-08-07 | Machek James Edward (VP-Research & Development) | Sale | 1,250 | 12.63 | 15,787 |
| 2015-05-26 | Wilder Thomas | Sale | 3,790 | 16.08 | 60,943 |
| 2015-05-20 | Lima Jose A. (VP-Quality) | Sale | 1,872 | 16.75 | 31,356 |
| 2015-05-20 | Waller Gregory D | Sale | 15,853 | 16.70 | 264,745 |
| 2015-05-20 | Waller Gregory D | Option Ex | 15,853 | 8.26 | 130,945 |
| 2015-04-06 | Mitchell Robert D (President) | Sale | 15,000 | 18.00 | 270,000 |
| 2015-04-01 | Mitchell Robert D (President) | Sale | 30,000 | 17.00 | 510,000 |
| 2015-03-13 | Fauls Janet Mary (VP Regulatory Affairs) | Sale | 15,000 | .00 | 0 |
| 2015-03-13 | Fauls Janet Mary (VP Regulatory Affairs) | Option Ex | 15,000 | 4.36 | 65,400 |
| 2014-12-12 | Love Charles Steele (VP-Clinical Affairs) | Sale | 10,000 | 13.96 | 139,550 |
| 2014-11-18 | Love Charles Steele (VP-Clinical Affairs) | Buy | 2,000 | 11.69 | 23,380 |
| 2014-11-04 | Mcdermott John D (Chief Executive Officer) | Buy | 25,000 | 11.25 | 281,250 |
| 2014-11-04 | Neels Guido J | Buy | 10,000 | 11.21 | 112,100 |
| 2014-08-04 | Wilder Thomas | Sale | 3,500 | 13.68 | 47,880 |
| 2014-06-12 | Mitchell Robert D (President) | Sale | 18,271 | 14.23 | 259,996 |
| 2014-06-10 | Mitchell Robert D (President) | Sale | 8,516 | 14.20 | 120,927 |
Insider trading activities including stock purchases, stock sales, and option exercises of ELGX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Endologix Inc /de/ (symbol ELGX, CIK number 1013606) see the Securities and Exchange Commission (SEC) website.